ArticleNaunyn-Schmiedeberg's archives of pharmacology2026

Efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis with a high drug interruption rate during the COVID-19 pandemic: a post hoc analysis from a single center of a phase III trial.

Shangshang Wang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.